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“Do not believe in anything simply because you have 
heard it. Do not believe in anything simply because it is 
spoken and rumored by many. Do not believe in 
anything simply because it is found written in your 
religious books. Do not believe in anything merely on 
the authority of your teachers and elders. Do not 
believe in traditions because they have been handed 
down for many generations. But after observation and 
analysis, when you find that anything agrees with 
reason and is conducive to the good and benefit of one 
and all, then accept it and live up to it.”  
Buddha
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1. Resumo 
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Introdução: O declínio cognitivo associado ao diagnóstico e tratamento do cancro da mama 
tem sido cada vez mais descrito. O objetivo deste estudo foi quantificar a associação entre 
tratamentos do cancro e declínio cognitivo em doentes com cancro da mama em estádios 
iniciais, durante um ano de seguimento, tendo em conta o potencial de modificação de efeito 
da ansiedade antes do tratamento. 
Participantes e Métodos: Foi realizado um estudo de coorte prospectivo, que incluiu 506 
mulheres com cancro da mama recém-diagnosticado, seguidas por um ano. As doentes 
foram avaliadas com a Escala de Ansiedade e Depressão Hospitalar (HADS) e Montreal 
Cognitive Assessment (MoCA), antes de iniciar o tratamento e após um ano de seguimento. 
Descrevemos valores padronizadas da variação média de cada subdomínio MoCA entre as 
duas avaliações, e usámos regressão de Poisson para calcular riscos relativos (RR) e 
Intervalos de confiança a 95% (IC 95%) para a relação entre diferentes características das 
doentes e dos tratamentos e o declínio cognitivo, de acordo com o estado da ansiedade das 
doentes no início do estudo. 
Resultados: Durante o primeiro ano após o diagnóstico, 34 doentes apresentaram declínio 
cognitivo e 38,0% foram classificadas como tendo ansiedade antes do tratamento. Dentro de 
cada subdomínio do MoCA, os participantes com declínio cognitivo tiveram uma variação 
significativamente mais elevada nos subdomínios de atenção e memória, entre aqueles sem 
ansiedade, e para a atenção, visuoespacial / função executiva e orientação, para aqueles 
que estavam ansiosos. A presença de ansiedade no início do estudo não se associou de 
forma estatisticamente significativa com o declínio cognitivo (RR = 1,43 IC 95%: 0,73, 2,81), 
mas o  efeito da quimioterapia foi modificado pelos níveis de ansiedade (P para interação = 
0,030), sendo o RR para a quimioterapia mais elevado entre as doentes não ansiosas antes 
do tratamento (RR ajustado = 4,35, 95% CI: 1,26, 15,02, para os regimes incluindo 
doxorrubicina + ciclofosfamida). 
Conclusões: A ansiedade antes do tratamento modificou a associação entre quimioterapia 
e declínio cognitivo; entre as mulheres não ansiosas no início do estudo o risco de declínio 
cognitivo foi mais de quatro vezes maior entre os pacientes submetidos à quimioterapia com 
esquemas incluindo doxorrubicina e ciclofosfamida. 
 
Palavras-chave: Cancro da mama; Disfunção cognitiva; Ansiedade; Quimioterapia
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2. Abstract 
12	  	  
Background: Cognitive decline associated with breast cancer diagnosis and treatment has 
been increasingly described. We aimed to quantify the association between cancer 
treatments and cognitive decline in early stage breast cancer patients during the first year of 
follow-up, taking into account the potential effect modification of anxiety before treatment. 
Patients and Methods: We conducted a prospective cohort study that included 506 women 
with newly diagnosed breast cancer, followed for one year. Patients were evaluated with the 
Hospital Anxiety and Depression Scale (HADS) and the Montreal Cognitive Assessment 
(MoCA) before starting treatment and at the 1-year follow-up. We described standardized 
scores of the mean variation in each MoCA subdomain between the two evaluations, and 
used Poisson regression to compute adjusted relative risks (RR) and corresponding 95%CI 
for the relation between different patients’ and treatments’ characteristics and cognitive 
decline, according to the patients’ anxiety status at baseline. 
Results: During the first year after diagnosis, 34 patients presented cognitive decline and 
38.0% were classified as having anxiety prior to treatment. Within each subdomain of the 
MoCA, the participants with cognitive decline had a significantly higher variation in the 
attention and memory subdomains, among those without anxiety, and for attention, 
visuospatial/executive function and orientation, for those anxious. The presence of anxiety at 
baseline was not significantly associated with cognitive decline (RR=1.43 95%CI: 0.73, 2.81), 
but modified the effect of chemotherapy (P for interaction=0.030), with the RR for 
chemotherapy being higher among patients with no anxiety prior to treatment (adjusted 
RR=4.35, 95%CI: 1.26, 15.02, for schemes including doxorubicin + cyclophosphamide). 
Conclusions: Anxiety modified the association between chemotherapy and cognitive 
decline; among women with no anxiety at baseline the risk of cognitive decline was four-fold 
higher among patients undergoing chemotherapy with schemes including doxorubicin and 
cyclophosphamide. 
 
Keywords: Breast cancer; Cognitive dysfunction; Anxiety; Chemotherapy 
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3. Introduction 
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3.1. Burden of Breast Cancer  
 
3.1.1. Incidence 
 
Breast cancer is worldwide the most common cancer among women; in 2012, there 
were about 1.67 million new cases (25.1% of all cases of cancer among women) and around 
six thousand (29.4% of all cases of cancer among women) only in Portugal (1, 2). 
The incidence has increased in the last decades, especially in the more developed 
countries (3-5). These trends are largely influenced by overdiagnosis due to the use of 
mammography for screening since the 1990s (6-8). In addition, trends in the exposure to 
many risk factors for breast cancer such as reproductive factors like lower parity, use of 
postmenopausal hormone therapy and others such as obesity, physical inactivity (9-13) and 
also dietary factors, like alcohol consumption, are also related with this increased incidence 
(14-18). Despite that increase, in some countries, including the United States of America 
(USA), the United Kingdom (UK), France and Australia, the incidence rates decreased from 
the beginning of the millennium mainly due to lower use of combined postmenopausal 
hormone therapy (19-23). 	  
 
Figure 1. Breast cancer estimated age-standardized incidence rates worldwide per 100 000 
in 2012 [Source: GLOBOCAN 2012 (IARC)]. 
 
The estimated age-standardized (Directed standardization, World standard 
Population) incidence rate of breast cancer in 2012 by region is detailed in Table 1. The 
highest are in Northern America (91.6 per 100 000) and Western Europe (91.1 per 100 000), 
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and the lowest incidence in Eastern Asia (27 per 100 000). This wide variation of Incidence 
rates across the world regions is also showed in Figure 1. 
In Europe, Belgium (111.9 per 100 000), Denmark (105.0 per 100 000) and The 
Netherlands (99.0 per 100 000) have the highest estimated incidence rates, while Bosnia 
Herzegovina (37.4 per 100 000), the Republic of Moldova (38.7 per 100 000), and Ukraine 
(41.3 per 100 000) have the lowest (1, 2). 
 
 
 
 
 
Table 1. Estimates of breast cancer incidence among women in 2012, by region. [Source: 
GLOBOCAN 2012 (IARC)]. 
INCIDENCE 
REGION NUMBER OF 
CASES 
CRUDE 
INCIDENCE 
RATE (/100 000) 
AGE-
STANDARDIZED* 
INCIDENCE RATE 
(/100 000) 
Northern America  256 222 144.5 91.6 
Western Europe  156 045 161.3 91.1 
Northern Europe  78 249 153.6 89.4 
Australia/New Zealand  17 550 127.6 85.8 
Southern Europe  100 807 125.9 74.5 
South America  115 881 57.1 52.1 
Central and Eastern 
Europe  
123 617 79.2 47.7 
Western Asia  42 485 36.6 42.8 
Africa  133 890 25.0 36.2 
South-Eastern Asia  107 545 35.3 34.8 
Central America  24 891 30.7 32.8 
South-Central Asia  223 899 25.3 28.2 
Eastern Asia  277 054 36.0 27.0 
World  1671 149 47.8 43.1 
* World standard population	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3.1.2. Survival 
 
The survival of breast cancer patients has been improving in the last decades mainly 
due to the advances in treatment and early detection through screening programs (6-8, 24, 
25). According to the data available from the CONCORD-2 study (26), very wide variations in 
survival were reported across countries. The average 5-year standardized [international 
standard for cancer survival analysis (ICSS)] relative survival for women diagnosed during 
1995–2009, follow-up to 2009 or one year later was calculated in 3 periods of diagnosis, from 
1995-1999, 2000-2004 and 2005-2009. For women diagnosed during 2005–09, age-
standardised 5-year net survival from breast cancer was 80% or higher in 34 countries with 
the Canada (88.6%), Sweden (86.2%) and USA (85.8%) as examples and less than 50% in 
Mongolia (56.5%), South Africa (53.4%), Algeria (59.8%) and Jordan (43.1%). Survival also 
rose in Europe but was generally lower than in North America and Oceania and with a much 
wider geographic range A different study reported a 5-year relative survival for women 
diagnosed with breast cancer during 1985–89 of 73% in Europe (weighted mean for 17 
countries) (27) and 84% in the USA (28).  
According to the EUROCARE study, among women diagnosed with breast cancer 
during the period of 1978–1989, relative survival improved more in Western than Northern 
Europe (7.4% to 3.9% respectively) and the European mean 5-year age-standardized (ICSS) 
relative survival had an absolute increase of 8.9% when compared women diagnosed with 
breast cancer in the period of 1987–1989 (73.5%) and those diagnosed between 1978–1980 
(64.6%) (29). This pattern of variation is likely to be explained mainly by a trend towards an 
earlier stage at diagnosis and, for women over age 50 years, better access to screening (30). 
The most recent estimates, from EUROCARE-5, also reported an increase in survival rates 
and a wide variation of this data among European countries. The average 5-year 
standardized (ICSS) relative survival for European women with breast cancer diagnosed 
between 2000-2007 and followed-up to December 2008 was 81.8%; however, there were 
large differences between countries, with 5-year age-standardized (ICSS) relative survival 
ranging from 66.7% in Lithuania to 87.2% in Iceland as showed in Table 2 (24). 	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Table 2. Five-year age-standardized* relative survival for women with breast cancer, 
diagnosed 2000-2007, by country [Source: EUROCARE - 5]. 
 
COUNTRY 5-YEAR AGE- STANDARDIZED * 
RELATIVE SURVIVAL  
  
European mean 81.8 (81.6-82.0) 
Iceland 87.2 (83.1-90.4) 
Sweden 86.0 (85.4-86.5) 
England 79.3 (79.0-79.5) 
Ireland 79.0 (77.8-80.1) 
France 86.1(85.4-86.8) 
Germany 83.6 (83.2-84.0) 
Italy 85.5 (85.1-85.8) 
Portugal 83.3 (82.4-84.2) 
Bulgaria 71.7 (70.6-72.7) 
Latvia 69.3 (67.4-71.1) 
Lithuania 66.7(65.1-68.2) 
* International standard for cancer survival analysis 
 
These regional differences suggest heterogeneity in the availability of diagnostic and 
therapeutic facilities, and also in the effectiveness of healthcare systems (4, 29, 31, 32). 
 
3.1.3. Mortality 
 
Breast cancer is still the leading causes of cancer death among women. It was 
responsible for 522 000 women deaths worldwide in 2012 and 1570 (16% of all cases of 
cancer among women) just in Portugal. It is now the second cause of cancer death in more 
developed regions (197 618 deaths, 15.4%) after lung cancer, but is still the most frequent 
cause of cancer death in women in less developed regions (324 289 deaths, 14.3% of total) 
(1, 2). However, during the last two decades, a substantial reduction in breast cancer 
mortality was observed in most of the more developed countries as depicted in Figure 2.  
 
18	  	  
 
Figure 2. Trends in mortality from female breast cancer in selected European countries: age-
standardized rate (World reference population) per 100 000 [Source: GLOBOCAN 2012 
(IARC)]. 
 
There are still disparities between countries, as for incidence and survival (33-35) as 
shown in table 3.The variation in mortality rates across world regions is lower than that the 
observed for incidence because of the more favourable survival rates of breast cancer in 
(high-incidence) developed regions (1, 2).  
In Europe the highest mortality rates are in Macedonia (25.5 per 100 000), Serbia 
(22.0 per 100 000) and Belgium (20.3 per 100 000), while the lowest are in Spain (11.8 per 
100 000), Bosnia Herzegovina (12 per 100 000) and Norway (12.5 per 100 000) (1, 2). 
 
 
 
 
 
 
 
 
 
19	  	  
Table 3. Estimates of breast cancer mortality among women in 2012, by region [Source: 
GLOBOCAN 2012 (IARC)]. 
 
MORTALITY 
 
REGION NUMBER OF 
DEATHS 
CRUDE 
MORTALITY RATE 
(/100 000) 
AGE-
STANDARDIZED*
MORTALITY RATE 
(/100 000) 
Western Africa  20 524 12.9 20.1 
Northern Africa  15 577 15.0 17.4 
Northern Europe 17 915 35.2 16.4 
Western Europe 37 242 38.5 16.2 
Europe  131 347 34.2 16.1 
Oceania 4 329 23.0 15.6 
Eastern Africa  17 028 9.6 15.6 
Southern Africa  4 047 13.7 15.5 
Caribbean  3 928 18.5 15.1 
Western Asia 14 810 12.8 15.1 
Southern Europe 27 473 34.3 14.9 
Northern America  48 850 27.5 14.8 
Australia/New 
Zealand 
3 620 26.3 14.5 
South America  32 014 15.8 14.0 
Asia 231 013 11.1 10.2 
Central America  7 266 8.9 9.5 
Eastern Asia 68 531 8.9 6.1 
World  521 907 14.9 12.9 
* World standard population 
 
The decline in mortality has been a result of an increase in the proportion of cancer 
detected at earlier stages, through mammography screening, and improved treatment (6-8, 
24, 25). However, in many African and Asian countries increasing incidence and mortality 
rates have been observed (36), as a result of changes in reproductive patterns, increase in 
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the frequency of physical inactivity and obesity, as well as lack of screening programs (9-12, 
37). In many economically developing countries early detection through mammography can 
be cost prohibitive (38); the recommended early detection strategies in these countries 
include the promotion of awareness of early signs and symptoms and also screening by 
clinical breast examination, but not a wide spread of diagnostic imaging (39). Furthermore, 
these countries also have difficulties in affording a suitable health work force, both in 
qualitative and quantitative terms (39). 
 
3.2. Breast cancer treatment 
 
Treatment for breast cancer is dependent on many disease characteristics; it involves 
a multidisciplinary team and consists in a combination of surgery, chemotherapy, 
radiotherapy, endocrine therapy and immunotherapy. The main factors involved in treatment 
decision are stage of the disease, histologic and molecular subtypes, menopausal status, 
performance status and also the patients’ age (40-42).  
 
3.2.1. Surgery 
 
There are basically two options of surgical treatment for breast cancer, namely 
breast-conserving surgery or mastectomy, with or without lymph node dissection. However 
the optimal type of surgery for breast cancer patients is still a controversial topic (43). 
Until the 1980s the radical mastectomy was the first option choice for the treatment of 
breast cancer, but currently breast conservation surgery, in the form of segmental 
mastectomy, axillary node dissection, and radiation is often chosen over the modified radical 
mastectomy because is associated with similar survival, with less surgical and postsurgical 
complications (44-46). However, for those patients who are not candidates for breast 
conservative surgery or who choose not to conserve, mastectomy with breast reconstruction 
is a safe technique that provides a better cosmetic outcome without compromising 
oncological safety (47). 
A recent population-based retrospective study performed in Canada revealed a 
13.5% decrease in the use of mastectomy alone and a 42.0% increase in immediate breast 
reconstruction (48). 
Other topic that is known to have prognostic value for breast cancer is the 
involvement of axillary lymph node. The sentinel lymph node biopsy has been adopted as an 
alternative to axillary lymph node dissection for node staging (49-51), with improved 
postoperative quality of life for node-negative patients and even some node-positive groups 
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(52, 53). 
Surgery is just a step in the treatment of breast cancer patients and most of the times 
is combined with neoadjuvant or adjuvant therapies. Most women diagnosed with early stage 
disease, approximately 70% of Western European women, who undergo breast conserving 
surgery receive adjuvant treatment; about half receives radiotherapy alone and a third 
undergoes both chemotherapy and radiotherapy (54). In contrast, most women with late 
stage breast cancer have systemic chemotherapy in addition to surgery and other therapies 
(55) and a considerable part of them undergoes mastectomy due to large tumor size (relative 
to breast size), tumor multicentricity, inability to achieve negative surgical margins after 
multiple resections, prior radiation to the chest wall or breast and other contraindications to 
radiotherapy, or patient choice (54). 
 
3.2.2. Chemotherapy 
 
In the last decades there were improvements in treatment strategies and drugs used 
in chemotherapy (40). Nevertheless, the group of patients that benefit from chemotherapy is 
not well defined and sometimes discordant from group to group of experts and breast cancer 
societies (42). Adjuvant chemotherapy increases the survival rate in breast cancer patients 
and is currently administered to up to 60% of patients below the age of 60 years (56). An 
overview of clinical trials on this topic showed that for women under 50 years old treated with 
chemotherapy, an average of 2.3 months of relapse-free survival was gained, as well as 5.4 
months of overall survival within 10 years, when compared with those not receiving 
chemotherapy (57). 
The 12th International Breast Cancer Conference reached a consensus when 
chemotherapy should be used as part of treatment for breast cancer: high histological grade, 
high proliferation as measured by Ki-67, low hormone receptor status, “triple negative” status 
in invasive ductal carcinoma of usual forms and positive human epidermal growth factor 
receptor 2 (HER-2) (42). Nevertheless, other studies demonstrated an additional benefit of 
chemotherapy even in those with HER-2 negative tumors (58, 59). In addition, the findings of 
the latest Oxford Overview were also discordant and demonstrated that all patients, 
regardless of tumor stage, nodal status, estrogen receptor status, or age, appeared to have a 
relatively equal proportional benefit from the addition of chemotherapy (60, 61).  
According the timing of delivery of chemotherapy, a meta-analysis reported that the 
benefit provided by chemotherapy is similar regardless of the timing of its delivery, in the 
adjuvant or neoadjuvant setting (62). 
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3.2.3. Radiotherapy  
 
Radiotherapy is used both after breast-conserving surgery and after mastectomy for 
node-positive (four or more axillary lymph nodes involved) patients (42, 63), and T3 or T4 
tumors, independent of the nodal status (6). Although a study showed that, even when the 
number of axillary lymph nodes affected are lower than four, a 50% risk reduction was 
demonstrated when patients with some additional risk factors are submitted to whole breast 
radiotherapy post-mastectomy (64); these risk factors are young age, vascular invasion, low 
number of examined axillary lymph nodes and non-radical tumor excision (42, 64, 65). 
The risk of local recurrence decreases by two-thirds when radiotherapy is used as 
part of treatment (for low-risk patients — to below 0.5% per year), which translates into 5% 
reduction in 15-year breast cancer mortality (66, 67). 
Beyond chemotherapy, radiotherapy after local excision for ductal carcinoma in situ, 
compared with local excision alone, reduced the overall number of both invasive and non-
invasive recurrences in the ipsilateral breast (at a median follow-up of 4.25 years) (42, 66). 
Breast cancer mortality was also reduced with radiotherapy, however this effect on mortality 
is offset by an increase in vascular deaths, perhaps attributable to irradiation of the coronary, 
carotid, or other major arteries (68). 
 
3.2.4. Endocrine therapy 
 
The choice of drugs for endocrine therapy is based on the menopausal status of the 
patient (63). Tamoxifen, with or without ovarian function suppression, is recommended for 
premenopausal women with hormone-sensitive disease, and aromatase inhibitors – 
anastrozole, letrozole and exemestane – are the preferred for postmenopausal women (42, 
69). 
Over the last decades, treatment with tamoxifen for five years was shown to reduce 
overall breast cancer recurrence and mortality by about 50% and 30%, respectively (70). In 
the recent ATLAS trial, an additional five years of treatment with tamoxifen – totalizing a 10 
year-treatment – improved breast cancer survival by 2.8% (71). 
In the postmenopausal patients, besides tamoxifen, the aromatase inhibitors are used 
in the adjuvant treatment, as it was shown to improve disease free survival; however, overall 
survival was not shown to improve significantly (70, 72). In addition, aromatase inhibitors 
were not recommended in premenopausal patients (72, 73). 
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3.2.5. Immunotherapy 
 
Trastuzumab is a monoclonal antibody targeting HER-2 that has been proved to 
significantly improve the disease-free and overall survival of women with tumors 
overexpressing HER-2 in both early and metastatic breast cancer (74-77). In this group of 
patients, trastuzumab combined with chemotherapy was shown to reduces in half the risk of 
recurrence compared with chemotherapy alone and improved survival rate approximately 
30% (78-80); this translates into an approximately 10% absolute improvement in 3-year 
disease free survival and a 3% increase in 3-year overall survival (81-83). The use of 
trastuzumab without chemotherapy, if chemotherapy can be given, is not supported, but is 
acceptable in circumstances where chemotherapy cannot be delivered (42). 
The European Society of Breast Cancer Specialists recommended one year of 
treatment with adjuvant trastuzumab, together or after chemotherapy, in women with HER-2-
positive, node-positive or high-risk node-negative breast cancer (tumor size bigger than 1 
cm), left ventricular ejection fraction of at least of 55% or more and without important 
cardiovascular risk factors, regardless of age (84).  
 
3.3. Cognitive impairment 
 
Cognition is the mental action or group of abilities that are responsible for acquiring 
knowledge and understanding (85). Those are necessary to execute both simple and 
complex tasks and are fundamental to daily life. Examples of these abilities are attention, 
memory, perception, information process, language and executive function (86, 87). For this 
reason the cognitive impairment can cause a great impact on quality of life for decreasing 
people’s functionality. 
 
3.3.1. Cognitive impact of cancer treatment 
 
The physical toxic effects of systemic treatments of solid tumors are extensively 
studied, but its consequences on cognitive function are less well characterized (88, 89). 
Taken together, the currently available evidence suggests that some cancer treatments or 
combinations of them have negative effects on cognitive function (90, 91). 
In the past two decades, neuropsychological studies have accumulated evidence of 
cognitive deficits in cancer patients that have mostly been attributed to neurotoxic effects of 
chemotherapy (92-97). Although the association between the use of some drugs in 
chemotherapy for central nervous system (CNS) tumors and neurological complications, 
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such as cognitive dysfunction, is known (98); the effect of the drugs used for treatment of 
non-CNS cancer on cognitive function remains poorly understood as also the mechanisms 
that may be responsible for this complications. Some authors have been explaining 
chemotherapy-induced cognitive dysfunction as result of neuronal loss multiple risk factors 
such as cumulative dose, neurotoxic side effects of specific anticancer agents or interaction 
effects with other drugs or therapies. Furthermore, increased blood-brain barrier 
permeability, efficiency of cellular efflux pumps, DNA damage, telomere shortening and 
consequently accelerated aging, alteration of cytokine regulation, defects in neural repair, 
oxidative stress and chemotherapy-induced anaemia may play roles in the effects of 
chemotherapy on central nervous system function (99-103). 
Another challenge is making sense of heterogeneous results across studies. A 
growing number of investigations involving breast cancer patients have been showing 
decline or dysfunction of some cognitive functions after chemotherapy (92-97). However, 
other studies yielded conflicting findings (104-106). Heterogeneous results were also found 
regarding the persistence of cognitive dysfunction; while some studies reported a persistent 
cognitive impairment years after the treatment (95, 107), other investigations showed a 
recover of some cognitive domains after completion of chemotherapy (108, 109). These 
inconsistent results can be explained by many methodological differences (88, 110-113). 
First, different timing of patients’ assessments. Second, different tests evaluating the same 
domain, because some tests are more sensitive to practice than others. Third, distinct criteria 
of determining impairment or reliable change. Fourth, variability in sample characteristics, 
such as cancer stage, menopausal status, age, educational level and type of treatments 
received. Finally, choice of comparison groups; results may vary depending on whether 
patients are compared to normative data, healthy non-cancer controls, or cancer patients 
who do not receive chemotherapy. Hence, the overall estimated incidence of cognitive 
decline varies in the literature from 19% to 78% (114). 
Results of a recent meta-analysis (115) of cognitive impairment and decline in breast 
cancer women corroborates that different methodologies/study designs can lead to distinct 
findings. They found differences when analysed cross-sectional and prospective studies, with 
a significant association between adjuvant chemotherapy and cognitive impairment in cross-
sectional studies, whereas among prospective studies there was improvement of cognitive 
functioning from prior to after chemotherapy.  
It is also proposed that some specific combinations of drugs and the doses 
administered are important for cognitive decline. A study published in 2006 that tried to 
correlate scheme and dose characteristics, compared four groups of patients, two of them 
with patients with breast cancer and treated under different chemotherapy schemes, one of 
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healthy controls and the other with breast cancer but without using chemotherapy as part of 
treatment. A significant higher risk of late cognitive impairment than in the control group of 
matched primary breast cancer patients not treated with chemotherapy was observed in the 
group submitted to the therapeutic regimen of high doses of cyclophosphamide, thiotepa and 
carboplatin, but not in the remaining groups tested (116). That may reflect that different 
chemotherapy regimens and/or doses used in treatment have also distinct impact in the 
cognitive functions (117, 118) with higher dose associated with worse cognitive test 
performances (119). Other study found that patients randomized to receive standard-dose 
fluorouracil, epirubicin and cyclophosphamide chemotherapy showed no elevated risk 
compared with the control group. However, breast cancer patients treated with conventional 
adjuvant cyclophosphamide, methotrexate, 5-fluorouracil chemotherapy given in routine 
clinical practice also showed a higher risk of cognitive deficit than the matched control group 
of primary breast cancer patients not treated with chemotherapy (120).  
Recent investigations that include brain imaging have begun to yield tentative 
answers regarding the impact of chemotherapy in brain structure and behaviour. Changes of, 
cortical and subcortical areas of the brain were found, and also their activation and 
metabolism changed after chemotherapy when compared with health controls or not treated 
with systemic chemotherapy (121-125). Some of them showed that chemotherapy 
associated structural and functional brain changes are related to worse cognitive 
performance (126, 127). 
Not only chemotherapy has been studied as a cause of possible treatment-related 
cognitive dysfunction. Recently, cognitive impairment associated with radiotherapy not 
directed to brain areas has also been reported (128-131). In a longitudinal study, cognitive 
impairment was observed in 34% of 141 patients who underwent radiotherapy, and this was 
persistent at 1 year for half of them (132). According the persistence of the impairment, 
some studies suggested that cognitive function recovered during radiotherapy or shortly after 
radiotherapy (133), while in others they persisted several months or even several years after 
radiotherapy (96, 129-132). However, these differences reflect different methodologies used 
in these studies. 
Other treatment that has been studied in relation to cognitive dysfunction is endocrine 
therapy (134, 135). Estrogens have been shown to modulate mood, mental status and 
cognitive function (136-138). For postmenopausal women, hormone-replacement therapy 
improves attention, learning and memory (139-141), can lower the risk of Alzheimer’s 
disease and atherosclerosis, but its use to prevent dementia is not well established (88). 
Tamoxifen has been the principal drug of endocrine therapy for breast cancer for many 
years. However, there is controversy about the action of tamoxifen in cerebral tissue. The 
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available studies suggest that current use of tamoxifen can cause neurotoxicity (142, 143) 
and might impair cognitive function, but its effect could be reversible after treatment is 
stopped (144). 
Even though the studies are not concordant about the effect of treatment in cognitive 
decline (110, 111), the available evidence suggests that cancer-treatment related cognitive 
dysfunction exists and need to be more deeply studied with standard methodologies so we 
can compare the results and finally consensually understand the mechanisms and better 
manage the complications of cognitive dysfunctions in patients daily life. 
 
3.3.2. Other risk factors for cognitive decline in cancer patients 
 
Many other factors, besides treatment, and potentially have an effect on the cognitive 
functioning of breast cancer patients among them the psychological burden of having cancer, 
disease-related biological factors such as elevated cytokines levels. Patients who receive 
chemotherapy seam to have an elevated risk of cognitive deficits, but not necessarily due to 
neurotoxic effects. These patients also have more advanced cancer stage, with a worse 
prognosis and a greater psychological burden. Breast cancer alone might threaten cognitive 
impairment as showed in previous studies with patients presenting cognitive dysfunctions 
even prior to treatment (145-147), however this risk increases with treatment, particularly 
with chemotherapy (92-97). Cognitive deficits in breast cancer patients may be caused by an 
accumulation of many of these factors. 
Other factors that have been considered responsible for this cognitive decline prior to 
treatment, as we mentioned before, can result from the cancer itself – paraneoplastic 
syndrome (148), increased levels of proinflammatory cytokines caused by the tumor (149) 
and anemia (150). Furthermore, presence of chronic disease, fewer years of education and 
aging (115, 151), menopause (152), anxiety and depression(153), fatigue, self-reported 
complaints or intelligence quotient are also explored as possible risk factors (151, 154). 
However, so far, no evidence of these predictors is well established and accepted. 
Anaemia has been implicated in the occurrence of cognitive dysfunction after 
chemotherapy, with patients who became anaemic showing significant declines in 
performance tests of attention and visual memory (150). However, a study reported 
significant relationship between anaemia and cognitive functioning even before breast cancer 
treatment (97). The proinflammatory cytokines (IL-1, IL-6, and TNF) can increase before 
chemotherapy, as well as the beginning of anemia, however they are also released by tumor 
tissue, which can cause mood and cognitive disorders (149, 155) increasing the risk for 
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cognitive impairment. Furthermore, paraneoplastic syndromes can lead to several 
neurological disorders (148).  
Genetic factors have been also studied as responsible to increase susceptibly to 
cognitive decline in breast cancer patients; one example is the E4 allele of apolipoprotein E 
that is responsible for Alzheimer’s disease and poorer cognitive outcomes (156) and also 
genetic polymorphisms related with cytokines functioning, DNA repair and neurotransmitters 
(157).  
The diagnosis of cancer itself is responsible for a great deal of emotional stress and 
anxiety, and many other factors, such as pain, insomnia, depression (154) and fatigue (158), 
might affect cognitive function. Nevertheless, symptoms of distress, anxiety, depression, or 
fatigue, did not appear to be associated with cognitive decline (104, 134, 147, 151, 159). 
Despite these results have been contradicted by a cross-sectional study that correlated 
anxiety and cognitive impairment (160). 
The frequent complaints of patients experiencing cognitive impairment during or after 
cancer treatment called the researchers and health professionals’ attention to understand the 
possible relation between perception of cognitive deficits and objective cognitive measures 
(161, 162); however, most of studies did not show an association between them (88, 104, 
105, 158, 163, 164). A review of 2010 reported that 21% to 90% of the patients reported 
subjective cognitive impairment and suggests that subjective cognitive dysfunction may be 
more indicative of emotional distress instead of objective cognitive decline (165). Other 
recent review evaluated 24 articles showing that only eight of these studies, mainly with 
breast cancer patients, found a significant relationship between objective and subjective 
measures of cognitive performance, with memory as the more important cognitive domain 
involved. Thus, perceived impairment may be an indicator of psychological distress rather 
than cognitive impairment (166). This lack of consistent findings regarding the association 
between subjective complaints and objective cognitive tests could be explained by variations 
in assessment methods or the definition of impairment. Despite these discrepancies, 
patients' perceptions of impairment are important due to its significant impact on daily life 
functionality. This divergence between mostly subtle neuropsychological deficits and often 
dramatic subjective cognitive complaints as well as the lack of association between both in 
the majority of studies present one more unsolved puzzle in this field of research. 
Older age and less years of education are currently related to be risk factors for 
cognitive decline in breast cancer patients, a previous study that evaluated breast cancer 
patients prior any treatment found a significant association of those factors with poor 
performance in the cognitive test for direct attention; however, the presence of chronic 
disease, symptoms of distress as insomnia and fatigue were not significantly related with 
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decline of attention (151). Concerning that, studies among children and elderly patients have 
shown that both groups are susceptible to cognitive impairment (91, 167, 168), although the 
elderly were more vulnerable to cognitive problems after systemic treatments, especially 
those with advanced stage disease and multiple comorbidities (88). 
Many studies investigating cognitive decline in breast cancer patients have also 
evaluated the impact of fatigue, anxiety and depression on cognitive dysfunction with 
inconsistent results. Fatigue is the most frequently investigated factor, with studies reporting 
no significant association between fatigue and cognitive test performance (97, 106, 158). The 
same phenomenon happens with anxiety that was not proven to be predictor of cognitive 
impairment (151, 159), although could be an important factor that modifies the cognitive test 
performance (169, 170). 
Other factors that might increase vulnerability to cognitive side-effects include, 
intelligence quotient and educational status – it has been hypothesized that people with a 
higher intelligence quotient or level of education might have more “cognitive reserve”, 
protecting them from problems secondary to brain insult – as well as history of development 
disorders or learning disabilities, previous head trauma, or presence of neurological 
disorders (171). 
Cognitive changes associated with breast cancer and its treatment are still far from 
being fully understood and definitive evidence to prove exactly the mechanisms related to 
cognitive dysfunction has not been established yet. Further investigations are necessary to 
deepen the knowledge about clinically relevant topic. 
 
3.3.3. Emotional interference on cognitive tests performance   
 
Some researchers have been investigating the relationship between psychological 
disturbance and emotional factors with cognitive test performance (172-184), being the two 
more frequently studied factors anxiety and depression. Many theories, called cognitive 
interference theories, suggest that high levels of anxiety predict adverse effects on the 
performance of cognitive tasks, particularly those that make high demands on cognitive 
resources. Although the evidence is inconsistent (179, 185-187), the available results 
indicates that anxiety and depressive symptoms may be a contributor to disturb the 
performance in some cognitive tests, especially those that measure executive and memory 
function, might be significant (172, 173, 176, 178, 180). Therefore, clinical lore have advised 
to take specific steps to minimize its effect (188). 
Since the cognitive interference theories started to be spread in the scientific 
community, the potential impact of anxiety on neuropsychological tests performance started 
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to be an important issue among researchers. The attentional control theory (169, 170), for 
example, assumed that anxiety impairs efficient functioning of directed attentional system by 
decreasing the attention control. A review was concordant with this theory and suggested 
that anxiety makes memory performance more difficult because anxious people can be more 
distracted (less attentional capacity) for task performance and, therefore, perform less well 
than non-anxious individuals on tasks that make substantial demands on working memory for 
example (189). However, anxiety may not impair quality of performance when it leads to the 
use of compensatory strategies (e.g., enhanced effort; increased use of processing 
resources) (190). Clinicians suggests that cognitive deficits should be interpreted cautiously 
when comorbid mood symptoms are present, and many of them are reluctant to interpret 
attentional impairments in the presence of depressive or anxiety symptoms (191, 192). 
Most of the studies include different cognitive tests, which involve different domains of 
cognition. The most discussed domains to be affected by anxiety and depression are 
attention, memory, executive function and process speed; however, the first two appear to 
have more consistent findings across studies.  
Data linking anxiety with lower than expected performance on neuropsychological 
tests are especially described in tests of memory and learning (172, 177). Other studies 
found relationship between anxiety and worse than expected scores for different cognitive 
domains as attention and executive function (182, 193, 194), processing speed (195), 
reading comprehension (196) and also for working memory (193, 197-199). 
Some researchers have also noted a significant relation between depression and 
impaired attentional performance (172, 180, 200) with meta-analytic reviews suggesting a 
significant relationship between depression and memory impairment (184, 201, 202). 
However, there was considerable variability in the magnitude of deficits across the moderator 
variables (e.g., age, depressive subtype, patient status, and stimulus type), suggesting that 
depression may only be associated with certain aspects of memory functioning and/or that 
only particular subgroups of depressed individuals may evince such a relationship. A 
previous study with non-demented older participants from the general population found that 
males were more affected cognitively by depressive symptoms than females (203) and a 
second study reported that African Americans had significantly lower cognitive performance 
with the same level of anxiety when compared with European Americans (183) which is 
supportive with the proposal that some individual’s characteristics are important. 
Three studies assessed the impact of depression and anxiety on memory tests 
performance in different populations. According to their results, depression and anxiety are 
related with impairment of specific aspects of memory functioning. The first (204) used data 
from the Longitudinal Aging Study Amsterdam, a large epidemiological study of 3,107 elderly 
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citizens in Netherlands, and found that depression symptoms had significant main effects on 
almost all cognitive performance tests although anxiety was only important for learning and 
delayed recall. It was also suggested that anxiety has a curvilinear relationship with 
cognition, with medium level of anxiety improving the test results compared with high and low 
levels; however, depressive symptoms were always negatively associated with cognitive 
performance. The second study (205) assessed the association between anxiety and 
depression symptoms with memory and also executive functioning among older adults. Their 
findings suggested that anxiety and depression have relationships with poor results of 
memory functioning in community-dwelling older adults. The third study (177) assessed 3999 
veterans who completed the California Verbal Learning Test. The depressive symptoms had 
an adverse effect on immediate recall of new information and the total amount of acquisition; 
however, retrieval and retention were unaffected. On the other hand, anxiety did not have 
significant detrimental effects on any aspect of memory functioning. But, when depression 
was compounded by anxiety, there was an adverse effect also on the retrieval of newly 
learned information. So the presence of comorbid depressive and anxiety symptoms may 
exert a synergistic effect together on memory functioning 
All these findings corroborate with the importance of consider the effect of emotional 
factors, namely anxiety and depression, when we use cognitive tests to assess also cancer 
patients. Despite the lack of studies with this specific group of patients, it is possible to 
extend these results, especially because is expected more vulnerability to anxiety stress and 
depression for the diagnosis and treatment of a still stigmatic disease.
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4.  Objectives 
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Worldwide, breast cancer is the leading cause of malignant neoplasm among women. 
Earlier diagnosis of breast cancer has become more frequent, due to improved access to 
screening and population health education, and more effective treatments became available, 
which contributes to improved survival rates. However, in the course of treatment or even 
with just the diagnosis of breast cancer a series of complications appears, including 
neurological ones. A growing number of studies have been showing the decline of some 
cognitive functions in women treated for cancer and also the perception of cognitive 
impairment for many of these patients. However, it is still difficult to assess which are the risk 
factors related with these cognitive dysfunctions and even if it is the disease itself, the 
distress caused for the diagnosis or the treatment implemented that are responsible for the 
cognitive decline, assessed by cognitive tests. Maintenance of usual state of function is 
crucial for patients undergoing cancer treatment and affects their ability to lead a fulfilled 
occupational, social life and daily life. Therefore, elucidation of the effect of cancer therapy 
on cognitive function is becoming increasingly important.  
This dissertation aimed to quantify the association between cancer treatments and 
cognitive decline in early stage breast cancer patients during the first year of follow-up, taking 
into account the potential effect modification by anxiety before treatment.
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5. Manuscript 
 
Cognitive decline in the first year after diagnosis of early breast cancer, according to 
the patients’ anxiety levels: a prospective cohort study 
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ABSTRACT 
 
Background: Cognitive decline associated with breast cancer diagnosis and treatment has 
been increasingly described. We aimed to quantify the association between cancer 
treatments and cognitive decline in early stage breast cancer patients during the first year of 
follow-up, taking into account the potential effect modification of anxiety before treatment. 
Patients and Methods: We conducted a prospective cohort study that included women with 
newly diagnosed breast cancer, followed for one year. Patients were evaluated with the 
Hospital Anxiety and Depression Scale and the Montreal Cognitive Assessment (MoCA) 
before starting treatment and at the 1-year follow-up. We calculated standardized scores of 
the mean variation in each MoCA subdomain between the two evaluations, and used 
Poisson regression to compute adjusted relative risks (RR) and corresponding 95%CI for the 
relation between different patients’ and treatments’ characteristics and cognitive decline, 
according to the patients’ anxiety status at baseline. 
Results: During the first year after diagnosis, 34 patients presented cognitive decline and 
38.0% were classified as having anxiety prior to treatment. Within each subdomain of the 
MoCA, the participants with cognitive decline had a significantly higher variation in the 
attention and memory subdomains, among those with low levels of anxiety, and for attention, 
visuospatial/executive function and orientation, for those with higher scores for anxiety. The 
presence of anxiety at baseline was not significantly associated with cognitive decline 
(RR=1.43 95%CI: 0.73, 2.81), but modified the effect of chemotherapy (P for 
interaction=0.030), with the RR for chemotherapy being higher among patients with no 
anxiety prior to treatment (adjusted RR=4.35, 95%CI: 1.26, 15.02, for schemes including 
doxorubicin + cyclophosphamide). 
Conclusions: Anxiety modified the association between chemotherapy and cognitive 
decline; among women with no anxiety at baseline the risk of cognitive decline was four-fold 
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higher among patients undergoing chemotherapy with schemes including doxorubicin and 
cyclophosphamide. 
 
Keywords: breast cancer; cognitive dysfunction; anxiety; chemotherapy 
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INTRODUCTION 
Worldwide, breast cancer is the leading cause of malignant neoplasms among 
women, with an estimated 1.67 million new cases in 2012 (1). Due to improved access to 
early diagnosis (2) and effective treatment schemes (3), breast cancer survival increased 
over the past years, with the most recent 5-year relative survival estimates surpassing 80% 
in several developed countries (4). The growing number of women surviving breast cancer 
highlights the need of a comprehensive assessment of the burden related to cancer 
treatment, especially regarding conditions that may be associated with some degree of 
incapacity throughout life. 
Breast cancer and its treatment may be accompanied by several complications, 
including neurological impairment (5, 6), which affect the patients’ capacity to accomplish 
their daily life activities (7). Cognitive dysfunction has been documented among breast 
cancer patients (8), though its etiology remains unclear. Chemotherapy has been the 
treatment more consistently associated with cognitive decline among breast cancer patients 
(8-11), and the cognitive changes associated with it were named “chemobrain” (12). 
Although the findings are conflicting (13, 14); the heterogeneous results may, at least 
partially, reflect methodological differences between studies, namely regarding the definition 
of the outcome, the characterization of the exposure or the control of confounding (14-17). 
Besides chemotherapy, many other treatments and conditions have been postulated 
to be related with cognitive dysfunction, namely radiotherapy (18, 19), endocrine therapy (20, 
21), paraneoplastic syndromes (22), increased levels of pro-inflammatory cytokines, 
especially IL-1, IL-6 and TNF (23) and also anxiety and depression (11); however, the 
findings are inconsistent. 
Although anxiety was not been proven to be a risk factor for cognitive dysfunction (24, 
25), cognitive interference theories suggest that high levels of anxiety are associated with 
poorer performance in cognitive tests, by decreasing attentional control (26, 27); therefore, 
the anxiety levels prior to treatment may act as an effect modifier in the assessment of risk 
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factors for cognitive decline. 
We aimed to quantify the association between cancer treatments and cognitive 
decline in early stage breast cancer patients during the first year of follow-up, taking into 
account the potential effect modification by anxiety before treatment. 
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METHODS 
We conducted a prospective cohort study of women with newly diagnosed breast 
cancer, followed for one year, as previously described in detail (28). 
 
Assembling of the cohort 
Participants were consecutively recruited in 2012, among the women, aged 18 years 
or older, admitted to the Breast Clinic of the Portuguese Institute of Oncology of Porto, 
Portugal, with newly diagnosed breast cancer proposed for surgery. We excluded those 
previously treated for cancer and those scoring less than 17, or less than 16 for women over 
65 years of old, in the Montreal Cognitive Assessment (MoCA) (N=82), which was assumed 
to correspond to a high probability of cognitive impairment at baseline (before treatment). We 
further excluded one woman with missing data on anxiety at baseline, and two with cancer 
stage IV; data from 418 participants was therefore available for the present analysis. 
 
Data collection 
Sociodemographic data was collected at baseline, using a structured questionnaire. 
Information on breast cancer stage and management were collected from clinical records. 
The Hospital Anxiety and Depression Scale (HADS) (29, 30) was used to 
characterize anxiety at baseline and at 1-year of follow-up; scores range from 0 to 21, and a 
score greater than or equal to 11 in the respective anxiety subscale was considered a case 
of anxiety. 
The MoCA was the instrument used to evaluate different cognitive subdomains 
(attention, concentration, executive functions, memory, language, visuoconstructional skills, 
conceptual thinking, calculations, and orientation), at baseline and in the 1-year follow-up 
evaluation. Cognitive decline was considered to have occurred when the MoCA scores 
(ranges from 0 to 30) of the patient decreased to values 1.5 standard deviations below age 
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and education adjusted cut-offs for possible cognitive impairment, during the first year after 
the initial assessment (31). 
 
Statistical analysis 
Standardized scores of the mean variation in each subdomain of cognitive function 
between the baseline assessment and the 1-year follow-up evaluation were calculated [z-
score = (x-µ/ ), where x is the variation in the subdomain for each participant and µ and σ 
are the mean and the standard deviation of the variation in the same subdomain for the 
whole sample, respectively], according to the presence of anxiety at baseline and cognitive 
decline during the first year of follow-up. The Wilcoxon signed-ranks test was used to 
compare z-scores for each subdomain between those with or without cognitive decline, and 
according to the presence of anxiety at baseline. 
We computed cumulative incidence estimates, and the corresponding 95% 
confidence intervals (95%CI), for cognitive decline at 1-year follow-up. Adjusted relative risks 
(RR) and corresponding 95%CI for the relation between different characteristics of the 
patients and the occurrence of cognitive decline were computed using Poisson regression, 
stratified by anxiety status at baseline; the variables included in each model are described in 
the footnotes of each table with these results. 
Statistical analyses were conducted using STATA®, version 11.2 (StataCorp, College 
Station, TX, USA). 
40	  	  
 
RESULTS  
All patients completed the one-year evaluation; the median (percentile 25-percentil 
75) time of follow-up was 371 days (362-385). 
 
Patients’ characteristics 
The main socio-demographic and clinical characteristics of the participants are 
presented in Table 1. At baseline, the mean (standard deviation) age of the patients was 
56.4 (11.3) and 73.7% had less than nine years of education. A total of 54.0% were 
diagnosed breast cancer at stage 0 or I, about half were submitted to mastectomy and just 
over one-third performed axillary lymph node dissection (ALND). 
Most patients went on to adjuvant treatment, mostly endocrine therapy (84.0%), 
radiotherapy (72.3%) or chemotherapy (89.7%). The most frequent chemotherapy scheme 
performed was 5-fluouracil (5-FU), cyclophosphamide, epirubicin and docetaxel (59.5%), 
followed by a combination of doxorubicin plus cyclophosphamide (20.7%). 
At baseline, approximately one-third of patients scored ≥11 in the HADS anxiety 
subscale. 
 
Incidence of cognitive decline and variation in the scores in each cognitive subdomain 
during the first year of follow-up 
During the first year after diagnosis, 34 patients presented cognitive decline (8.1%, 
95%CI: 5.8, 1.2). Among those with anxiety prior to any treatment, there was a decrease in 
the MoCA score in 36.5% of the participants, despite a median overall variation of 0. A total 
of 30.9% of those without anxiety at baseline had a reduction of the MoCA score with a 
median variation of 1 (Figure 1). 
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As depicted in figure 2, there was a significant decline in the scores of the abstraction 
subdomain of the MoCA test, regardless of the levels of anxiety at baseline and the presence 
of global cognitive decline defined using the MoCA score. Among subjects classified as 
having cognitive decline during the first year, the subdomains that presented significantly 
higher declines were attention and memory in patients with no anxiety at baseline; while 
declines in attention and visuospatial/executive function predominate among those with 
anxiety prior treatment. Within each subdomain, the participants with cognitive decline had a 
significantly higher variation in the subdomains attention and memory, among those with no 
anxiety, and for attention, visuospatial/executive function and orientations, for those with 
anxiety. 
 
Predictors of cognitive decline during the first year of follow-up 
Table 2 presents adjusted RR and the corresponding 95%CI for the relation between 
different socio-demographic and clinical characteristics of the patients and cognitive decline 
during the first year after enrolment, overall and according to the levels of anxiety at baseline. 
When considering the whole sample, there were no statistically significant differences 
according to any of the variables considered. The presence of anxiety at baseline was not 
significantly associated with cognitive decline (RR=1.43 95%CI: 0.73, 2.81), but modified the 
effect of chemotherapy (P for interaction=0.030), with the RR for chemotherapy being higher 
among patients with no anxiety prior to treatment. 
The relationship between different chemotherapy schemes and timing of its delivery, 
and the occurrence of cognitive decline were also analysed among patients without anxiety 
at baseline, as detailed in Table 3. There was no significant difference in the risk of cognitive 
decline according to the timing of chemotherapy, especially when RR estimates were further 
adjusted to the therapeutic schemes used (RR=1.66 95%CI: 0.40, 6.90 for patients 
submitted to neoadjuvant and RR=1.37 95%CI: 0.10, 17.99 for adjuvant chemotherapy). 
Concerning the different regimens of chemotherapy used, women treated with doxorubicin + 
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cyclophosphamide (with or without docetaxel) had a four-fold higher risk of developing 
cognitive decline than those not treated with chemotherapy and those treated with 5-FU + 
epirubicin + cyclophosphamide (with or without docetaxel) had a risk almost three times 
higher. 
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DISCUSSION 
The incidence of cognitive decline in the first year after diagnosis of breast cancer 
was 8.1%. At baseline, 38.0% of the patients were classified as having anxiety, and this 
condition significantly modified the association between chemotherapy and cognitive decline; 
among women with no anxiety at baseline, the risk of cognitive decline was three-fold higher 
for patients treated with specific chemotherapy schemes than those not receiving 
chemotherapy. 
Anxiety is one of the most common psychiatric disorders among breast cancer 
patients (32). In our study, 38% of the women were classified as having anxiety at baseline, 
which is a higher prevalence than that expected for the general female population (33). The 
high level of anxiety and distress in this population might be explained by the diagnosis of a 
possible chronic and fatal disease that, besides the great development in treatments and the 
increase in survival, is still a stigmatic and frightening disease that in the collective 
unconscious is a non-curable disease leading to death (34). 
Anxiety has been studied as a possible predictor of cognitive dysfunction (24, 25), as 
well as its interference with the performance of cognitive tests through declining attentional 
control (26, 27), particularly in those abilities that require a high degree of concentration and 
attention, such as executive and memory function (35-37). Therefore, cognitive deficits 
should be interpreted cautiously in the presence of depressive or anxiety symptoms (38, 39). 
In our study, we did not find an association between having anxiety at baseline and 
development of cognitive dysfunction, but patients with and without anxiety had different 
patterns of subdomain specific cognitive decline. Although attention declined in both anxious 
and not anxious women, visuospatial/executive function significantly declined in women with 
anxiety, while memory declined in women without anxiety prior treatment. Our results are 
concordant with other studies reporting that the cognitive subdomains more often affected 
are memory, attention, language, learning, executive function, processing speed (40, 41). 
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Cognitive decline after 1-year follow-up was observed in 8.1% of the patients, which 
is lower than in previous prospective studies (ranging between 15% and 80%) (8-11). The 
variability in results could be explained by the fact that these studies had control groups of 
healthy women, did not use normative data to define the outcome, had distinct definitions of 
cognitive decline or had different follow-up periods.  Methodological features such as the 
patients not being evaluated prior to treatment, and effect modification by other medical and 
psychological conditions, symptoms of distress as fatigue, or anxiety and also pain further 
contribute for heterogeneous results regarding the relation between chemotherapy and 
cognitive decline (14-17). 
Our results showed a statistically significant interaction between chemotherapy and 
patients’ status of anxiety at baseline. In order to better understand if this reflects the effect of 
baseline levels of anxiety or its variation during follow-up, we explored the HADS score 
variation between baseline and one-year evaluation. There was a similar result in mean 
score variation between both groups of patients, those that had cognitive decline and those 
that had not, according to the presence of anxiety. Among anxious women, the mean 
variation was -3.41 (3.99), those that had cognitive decline at one-year presented a mean 
variation of -3.56 (4.99) and those without decline -3.31 (4.02). The same pattern appeared 
in women not anxious at baseline. This is important to show that anxiety, despite not having 
been taken into account at the one-year MoCA evaluation, had a similar variation in the 
groups of patients compared. 
In previous studies, dose-dependent peripheral neuropathy has been associated with 
taxanes (42, 43); however, only reversible neurological symptoms including confusion or 
behavioural changes were reported (44). Investigations with therapeutic schemes containing 
5-FU also found an increased risk of cognitive impairment when compared with the control 
group (45). In our study, although an increased risk of cognitive decline was observed for 
different treatment modalities and schemes, the strongest association was observed for 
treatment including doxorubicin and cyclophosphamide, regardless of the use of taxanes. 
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Direct comparisons with previous reports are difficult due to differences in the study design 
and strategies of data analysis. Also, the lack of sufficient comparative data makes 
assessment of the relative contribution of each agent almost impossible and we cannot 
exclude the possibility that these observed results were found by chance. 
The major methodological strengths of our study are the prospective design, with an 
evaluation of patients before any treatment and after a 1-year follow-up, and a nearly 
complete follow-up. However, some limitations need to be addressed, especially regarding 
the external validity of the results. Our study evaluated essentially women with early breast 
cancer, which limits the generalization to patients with more advanced disease; however it 
eliminates the chance of cognitive declines due to direct metastatic disease. Learning effects 
may have contributed to underestimate the incidence of cognitive decline, which depended 
on evaluations with the same instrument at different moments, though these are expectedly 
of small importance taking into account the one-year lag between evaluations. 
In conclusion this study shows that the association between chemotherapy and 
cognitive decline was modified by anxiety at baseline. Among women with no anxiety at 
baseline, the risk of cognitive decline was four-fold higher among patients undergoing 
chemotherapy with schemes including doxorubicin and cyclophosphamide. 
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Table 1. Demographic and medical characteristics of breast cancer patients with normal 
cognitive function for their age and education at baseline (N=418). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 N (%) 
Age (years)  
 ≤55 201 (48.1) 
 >55 217 (51.9) 
Education (years)  
 ≤4 196 (46.9) 
 5-9 112 (26.8) 
 ≥10 110 (26.3) 
Cancer stage  
 0 29 (6.9)**  
 I 197 (47.1) 
 II 132 (31.6) 
 III 60 (14.4) 
Breast surgery*  
 Breast-conserving 212 (50.7) 
 Mastectomy 206 (49.3) 
Axillary surgery† [N=404]  
 Sentinel lymph node biopsy 265 (65.6) 
 Axillary lymph node dissection 139 (34.4) 
Chemotherapy 242 (57.9) 
 Timing of chemotherapy  
 Neoadjuvant 25 (10.3) 
 Adjuvant 217 (89.7) 
 Chemotherapy schemes  
 Doxorubicin + cyclophosphamide ‡ 50 (20.7) 
 Doxorubicin + cyclophosphamide + docetaxel § 24 (9.9) 
 Doxorubicin + cyclophosphamide + paclitaxel ¶ 1 (0.4) 
 Cyclophosphamide + docetaxel ¥ 1 (0.4) 
 Carboplatin + docetaxel ¢ 1 (0.4) 
 5-FU + epirubicin + cyclophosphamide ♯ 20 (8.2) 
 5-FU + epirubicin + cyclophosphamide + docetaxel ς 144 (59.5) 
 5-FU + cyclophosphamide + methotrexate & 1 (0.4) 
Radiotherapy 303 (72.5) 
Brachytherapy 82 (19.6) 
Endocrine therapy 351 (84.0) 
Immunotherapy 55 (13.2) 
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* Patients who had both mastectomy and breast-conserving surgery are reported as mastectomy; 
† Patients who had both axillary lymph node dissection and sentinel lymph node dissection are reported as axillary 
lymph node dissection; does not sum 100.0% because 14 patients only performed breast surgery; 
‡ Four cycles of concomitant doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2); 
§ Four cycles of concomitant doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), followed by four cycles 
of docetaxel (100 mg/m2); 
¶ Four cycles of concomitant doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), followed by four 
cycles of Paclitaxel (80 mg/m2); 
¥ Four cycles of concomitant cyclophosphamide (600 mg/m2) and docetaxel (75 mg/m2); 
¢ Six cycles of concomitant docetaxel (75mg/m2) and carboplatin (212mg/m2); 
♯ Six cycles of concomitant 5-FU (500 mg/m2), epirubicin (100 mg/m2), and cyclophosphamide (500 mg/m2); 
ς Three cycles of concomitant 5-FU (500 mg/m2), epirubicin (100 mg/m2), and cyclophosphamide (500 mg/m2) 
followed by three cycles of docetaxel (100 mg/m2); 
& Six cycles of concomitant 5-FU (600 mg/m2), cyclophosphamide (600 mg/m2) and methotrexate (40 mg/m2); 
** Cancer stage of one patient is based on clinical information because she abandoned the study before the post-
surgery evaluation.
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Figure 1. Variation between MoCA score at baseline and at one-year of follow-up, according 
to the patients’ anxiety status at baseline (N=418). 
 
MoCA, The Montreal Cognitive Assessment. 
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Figure 2. Variation of cognitive domains, according to the patients’ anxiety status at baseline and the occurrence of cognitive decline during the first-
year follow-up (N=418). 
 
P-value of the comparison between z-scores of those with or without cognitive decline, computed using Wilcoxon signed-rank test. 
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Table 2 Adjusted relative risks (RR) and corresponding 95% confidence intervals (95%CI) for the 
relation between different characteristics of the patients and the occurrence of cognitive decline 
(CD)* during the first year after enrolment, according to the patients anxiety at baseline (N=418). 
   Anxiety at baseline  
 All patients (N=418) No (N=259) Yes (N=159)  
 Patients with CD [N(%)] Adjusted RR (95%CI) Adjusted RR (95%CI) Adjusted RR (95%CI) P for 
interaction 
Anxiety at baseline (HADS)      
 No 18 (7.0) 1 (ref.)    
 Yes 16 (10.1) 1.43 (0.73,2.81)¶    
Age (years)      
 ≤55 18 (9.0) 1 (ref.) 1 (ref.) 1 (ref.)  
 >55 16 (7.4) 0.82 (0.42,1.61) 1.11 (0.44,2.82) 0.59 (0.22,1.63) 0.368 
Education (years)      
 ≤4 15 (7.6) 1 (ref.) 1 (ref.) 1 (ref.)  
 5-9 10 (8.9) 1.08 (0.46,2.56)‡ 1.24 (0.37,4.20)‡ 1.03 (0.31,3.45)‡  
 ≥10 9 (8.2) 0.99 (0.41,2.40)‡ 1.61 (0.49,5.34)‡ 0.62 (0.16,2.46)‡ 0.697 
Cancer stage      
 0/I 21 (9.3) 1 (ref.) 1 (ref.) 1 (ref.)  
 II/III 13 (6.8) 0.70 (0.34,1.40)§ 1.16 (0.46,2.96)§ 0.35 (0.11,1.09)§ 0.158 
Surgery† [N =404**]      
 Breast conserving + SLNB 17 (10.8) 1 (ref.) 1 (ref.) 1 (ref.)  
 Breast conserving+ ALND 3 (7.3) 0.82 (0.19,3.59)¶ 0.69 (0.07,6.91)¶ 1.34 (0.11,16.28)¶  
 Mastectomy + SLNB 6 (5.6) 0.54 (0.21,1.40)¶ 1.13 (0.34,3.83)¶ 0.15 (0.02,1.14)¶  
 Mastectomy + ALND 7 (7.1) 0.81 (0.25,2.64)¶ 1.24 (0.28,5.60)¶ 0.59 (0.07,4.72)¶ 0.180 
Chemotherapy      
 No  14 (8.0) 1 (ref.) 1 (ref.) 1 (ref.)  
 Yes 20 (8.2) 1.23 (0.56,2.73)¶ 2.92 (0.88,9.70)¶ 0.49 (0.14,1.74)¶ 0.030 
Radiotherapy [N =404**]      
 No 9 (7.8) 1 (ref.) 1 (ref.) 1 (ref.)  
 Yes 25 (8.2) 0.82 (0.31,2.17)¥ 0.77 (0.23,2.56)¥ 0.91 (0.18,4.65)¥ 0.282 
Brachytherapy [N =404**]      
 No 25 (7.4) 1 (ref.) 1 (ref.) 1 (ref.)  
 Yes 9 (11.0) 1.33 (0.55,3.22)¥ 0.66 (0.13,3.33)¥ 1.79 (0.57,5.59)¥ 0.055 
Endocrine therapy      
 No 7 (10.4) 1 (ref.) 1 (ref.) 1 (ref.)  
 Yes 27 (7.8) 0.75 (0.33,1.73)¶ 0.42 (0.16,1.11)¶ 2.78 (0.36,21.11)¶ 0.122 
Immunotherapy      
 No 31 (8.5) 1 (ref.) 1 (ref.) 1 (ref.)  
 Yes 3 (5.4) 0.66 (0.20,2.17)¶ 0.71 (0.16,3.12)¶ 0.55 (0.07,4.24)¶ 0.800 
 
HADS, Hospital Anxiety and Depression Scale; ALND, Axillary lymph node dissection; SLNB, Sentinel lymph node biopsy;  
* We consider cognitive decline the decrease from normal values at baseline to abnormal values at 1-year follow-up 
evaluation; 
† Those patients who had both mastectomy and breast-conserving surgery are reported as mastectomy and those who 
had both ALND and SLNB are reported as ALND; 
‡ Adjusted for age; 
§ Adjusted for age and education; 
¶ Adjusted for age and cancer stage; 
¥ Adjusted for age, cancer stage and surgery; 
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** N<418 because 14 patients only performed breast surgery.	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Table 3. Adjusted relative risks (RR) and corresponding 95% confidence intervals (95%CI) 
for the relation between different chemotherapy schemes and the occurrence of cognitive 
decline (CD)* during the first year after enrolment between those without anxiety at baseline 
(N=259). 
 
* We consider cognitive decline the decrease from normal values at baseline to abnormal values at 1-year follow-
up evaluation; 
† Four cycles of concomitant doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), followed by four cycles 
of docetaxel (100 mg/m2) or six cycles of concomitant docetaxel (75mg/m2) and carboplatin (212mg/m2); 
‡ Other chemotherapeutic schemes that were not four cycles of concomitant doxorubicin (60 mg/m2) and 
cyclophosphamide (600 mg/m2), followed by four cycles of docetaxel (100 mg/m2) or six cycles of concomitant 
docetaxel (75mg/m2) and carboplatin (212mg/m2); 
§ Adjusted for age and cancer stage.	  
 Patients with CD [N(%)] Adjusted RR (95%CI) 
Timing of chemotherapy   
 No chemotherapy 4 (3.7) 1 (ref.) 
 Neoadjuvant † 2 (13.3) 5.33 (0.77,37.05)§ 
 Adjuvant ‡ 12 (8.8) 2.86 (0.85,9.58)§ 
Chemotherapeutic regimen   
 No chemotherapy 4 (3.7) 1 (ref.) 
 Doxorubicin + cyclophosphamide (with or without docetaxel) 8 (15.4) 4.35 (1.26,15.02)§ 
 5-FU + epirubicin + cyclophosphamide (with or without 
docetaxel) 
6 (6.1) 1.72 (0.43,6.95)§ 
Docetaxel-based chemotherapy   
 No chemotherapy 4 (3.7) 1 (ref.) 
 Without docetaxel  6 (12.8) 3.59 (1.00,12.93)§ 
 With docetaxel 8 (7.8) 2.28 (0.58,9.06)§ 
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6. Conclusion 
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In conclusion, our study showed that the association between chemotherapy and 
cognitive decline was modified by anxiety before treatment. Among women with no anxiety at 
baseline the risk of cognitive decline was four-fold higher among patients undergoing 
chemotherapy with schemes including doxorubicin and cyclophosphamide. These results 
corroborate the findings from previous studies where chemotherapy was considered to be a 
risk factor for cognitive decline. However the anxiety status of the patient should be 
considered during the application of cognitive tests because it can interfere with patient’s test 
performance, and consequently with the assessment of the effect of treatment in cognitive 
function. 
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 Escala de Ansiedade e Depressão 
Hospitalar (HADS)  
 
 
 
Nome: _________________________________________________  Data: _____________  
Este questionário está concebido para ajudar o/a seu/sua médico/a a saber como você se sente. 
Leia todas as frases e sublinhe a resposta que melhor descreve a forma como se tem sentido nos 
últimos 7 dias. Ignore os números impressos ao lado de cada resposta. 
 
 
     
    1-Sinto-me tenso/a ou ansioso/a 
    □ Quase sempre 
    □ Muitas vezes 
    □ Por vezes 
    □ Nunca 
 
  
 2-Ainda sinto prazer nas coisas de que costumava 
gostar 
    □ Tanto como antes 
    □ Não tanto agora 
    □ Só um pouco 
    □ Quase nada 
 
  
 3-Tenho uma espécie de sensação de medo, como se 
algo de terrível estivesse prestes a acontecer 
    □ Sim e muito forte 
    □ Sim, mas não muito forte 
    □ Um pouco, mas não me preocupa 
    □ Não (de modo algum) 
    4-Consigo rir e ver o lado divertido das coisas 
    □ Tanto como antes 
    □ Não tanto como antes 
    □ Muito menos agora 
    □ Nunca 
    5- Tenho a cabeça cheia de preocupações 
    □ A maior parte do tempo 
    □ Muitas vezes 
    □ Por vezes 
    □ Quase nunca 
    6-Sinto-me animada 
    □ Nunca 
    □ Pouca vezes 
    □ De vez em quando 
    □ Quase sempre 
 
  
 7- Sou capaz de estar descontraidamente sentada e 
sentir-me relaxada 
    □ Quase sempre 
    □ Muitas vezes 
    □ Por vezes 
    □ Nunca 
     
8-Sinto-me como se estivesse mais lento/a 
 
   
Quase sempre □     
Muitas vezes  □     
Por vezes □     
Nunca □     
9- Sinto-me de tal forma apreensiva (com medo), que 
até sinto um aperto noestômago 
 
   
Nunca □     
Por vezes □     
Muitas vezese □     
Quase sempre □     
10- Perdi interesse em cuidar do meu aspecto físico     
Completamente □     
Não dou a atenção que devia □     
Talvez cuide menos do que antes □     
Tenho o mesmo cuidado de sempre □     
11- Sinto-me de tal forma inquieta que não consigo 
estar parada 
 
   
Muito □     
Bastante □     
Não muito □     
Nada □     
12-Penso com prazer nas coisas que podem acontecer 
no futuro 
 
   
Tanto como antes □     
 Não tanto como antes □     
Bastante menos agora □     
Quase nunca □     
13-Tenho sensações de pânico repentinas     
Muitas vezes □     
Bastantes vezes □     
Por vezes □     
Nunca □     
14- Sou capaz de apreciar um bom livro ou um 
programa de rádio ou de televisão 
 
   
Muitas vezes □     
De vez em quando □     
Poucas vezes □     
Quase nunca □     
 
 
Agora, verifique se respondeu a todas as perguntas  
    A D  
 TOTAL     
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